Aim: We investigated the long term clinical outcomes after implantation of the ABSORB- Everolimus Eluting Bioresorbable Vascular Scaffold (ABSORB BVS, Abbott Vascular, Santa Clara , CA, USA)
Background: The Absorb BVS is the first CE-approved scaffold in investigational and clinical practice. This stent has a bioabsorbable polymer backbone of PLLA (Poly-L- Lactic acid with a polymer coating of poly-D, L-lactide) that contained and controls the release of Everolimus.
Methods: We used the Absorb BVS in 21 patients\ 22 de novo lesions. Mean age was 64 years and 90% wer males. The six, one and two years clinical outcomes are reported. Data were collected prospectively as follow: cardiac death, MI, and ischemia-driven target Vessel/Lesion revascularization (TVR/TLR). Absorb BVS sizes were of 3.5x12, 3.0X18 or 28mm and 2.5X18 mm. Proximal and distal reference vessel diameter stenosis (Dmax) was between 2.5 to 3.3 mm and lesion length was less than 28mm.
Results: The majority of patients (75%) were presented with unstable angina. The overall procedural success was obtained in 100% and by intention to treat (meaning BVS implantation success) in 20 of 21 implants (96%) as the BVS became dislodged in one patient. At One year one patient had cardiac arrest, anterior wall MI, needed a TVR intervention with mace of 4%. Two years follow up was available for 13 pts. An additional patient had acute MI and primary intervention of TVR, with MACE rate of 12%.
Conclusions: In carefully selected patients, the preliminary results following the use of Absorb BVS are decent. No death encountered during follow up, two patients sustained MI events and two patients had ischemia driven TVR. Expanded data is needed to define the potential advantages of this technology.
